Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 11.52 CAD -1.54% Market Closed
Market Cap: 135.8m CAD
Have any thoughts about
Biosyent Inc?
Write Note

Net Margin
Biosyent Inc

21.1%
Current
20%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
21.1%
=
Net Income
7.2m
/
Revenue
33.8m

Net Margin Across Competitors

Country CA
Market Cap 133.5m CAD
Net Margin
21%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 749.7B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 372B USD
Net Margin
17%
Country US
Market Cap 257.3B USD
Net Margin
19%
Country CH
Market Cap 201.7B CHF
Net Margin
20%
Country UK
Market Cap 163B GBP
Net Margin
13%
Country CH
Market Cap 179.6B CHF
Net Margin
35%
Country US
Market Cap 146B USD
Net Margin
7%
No Stocks Found

Biosyent Inc
Glance View

Market Cap
133.5m CAD
Industry
Pharmaceuticals

BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.

RX Intrinsic Value
9.62 CAD
Overvaluation 17%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
21.1%
=
Net Income
7.2m
/
Revenue
33.8m
What is the Net Margin of Biosyent Inc?

Based on Biosyent Inc's most recent financial statements, the company has Net Margin of 21.1%.